Status:
COMPLETED
Disulfiram for Cocaine Abuse
Lead Sponsor:
University of Arkansas
Collaborating Sponsors:
National Institute on Drug Abuse (NIDA)
Conditions:
Cocaine Dependence
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
This study examines the influence of dopamine beta-hydroxylase enzyme activity on the clinical efficacy of the novel pharmacotherapy, disulfiram, for treating cocaine dependence in cocaine-dependent p...
Eligibility Criteria
Inclusion
- current users of cocaine, including having a cocaine-positive urine
- self-reported use of \> 7 gm during the preceding 6 months and \> 1 time/week in at least one month preceding study entry
- meet DSM-IV criteria for cocaine dependence
Exclusion
- current diagnosis of alcohol dependence
- significant medical conditions such as abnormal liver function
- active hepatitis
- hypertension
- a current cardiac condition or high risk of cardiovascular disease
- seizure disorders
- any another significant underlying medical condition which would contraindicate disulfiram or methadone treatment
- meeting DSM-IV psychiatric classifications for schizophrenia, bipolar disorder, or other psychotic disorders
- exhibiting current suicidality or homicidality
- pregnancy
- current use of a prescribed psychotropic medication (e.g., antidepressants, anxiolytics, antipsychotics, anticonvulsants, etc.) which cannot be discontinued current use of medications such as anticoagulants, isoniazid, metronidazole, clotrimazole, and paraldehyde.
Key Trial Info
Start Date :
April 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2011
Estimated Enrollment :
118 Patients enrolled
Trial Details
Trial ID
NCT00395850
Start Date
April 1 2007
End Date
December 1 2011
Last Update
November 13 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Arkansas for Medical Sciences
Little Rock, Arkansas, United States, 72205